Investigators from UC San Diego and UCLA report COVID-19 infection rates for a cohort of health care workers previously vaccinated for the novel coronavirus. Risk of infection is minuscule, but exists.
The vaccinator workforce is an essential component of the COVID-19 response and recovery. However, since administration of the two FDA-authorized COVID-19 vaccines began in December 2020, the rollout has encountered several challenges and failed to meet initial targets for total vaccinations provided. The current health workforce has been identified as one possible bottleneck for distributing the vaccine, prompting a general call to authorize as many healthcare professionals to administer the vaccine as possible. To track this fast-moving issue at the state level, researchers at the Fitzhugh Mullan Institute for Health Workforce Equity have created an interactive tool that displays temporary, emergency state policies authorizing specific professions to provide the COVID-19 vaccine.
接受第二剂信使RNA或mRNA COVID-19疫苗10天后，与未接种COVID-19疫苗的患者相比，无症状COVID-19感染者检测为阳性和在不知不觉中传播COVID-19的可能性大幅降低。Pfizer-BioNTech和Moderna信使RNA COVID-19疫苗已在美国获得紧急使用授权。
Dez dias após receber uma segunda dose de uma vacina para COVID-19 de RNA mensageiro, ou mRNA, pacientes sem sintomas de COVID-19 têm muito menos probabilidade de apresentar teste positivo e espalhar COVID-19 inadvertidamente, em comparação com pacientes que não foram vacinados para COVID-19.
بعد عشرة أيام من تلقي الجرعة الثانية من لقاح الحمض النووي الريبوزي المرسال، أو ما يُسمى بـ mRNA لفيروس كورونا المستجد (كوفيد-19)، فإن المرضى الذين لا يعانون من أعراض فيروس كورونا المستجد (كوفيد-19) هم أقل عرضة بأن تكون نتائجهم إيجابية للاختبار وأقل عرضة أن يقوموا بنشر فيروس كورونا المستجد (كوفيد-19) بشكل غير مقصود، مقارنةً بالمرضى الذين لم يتم تطعيمهم ضد فيروس كورونا المستجد (كوفيد-19). وقد تم التصريح لاستخدام لقاحات الحمض النووي الريبوزي المرسال "بيونتك" الخاصة بشركة فايزر ولقاح موديرنا في حالات الطوارئ في الولايات المتحدة.
Public participation is critical to the success of medical research. Yet recruiting volunteers for trials is increasingly challenging. New Washington University research suggests the widening ideological gap in the U.S. may be to blame.
More than 50 scientific experts from across the United States, including virologists, infectious disease specialists and medical doctors, are launching a series of virtual town halls today to answer the public’s questions about the COVID-19 vaccines.
Most people with cancer who are infected by the novel coronavirus produce antibodies at a rate comparable to the rest of the population—but their ability to do so depends on their type of cancer and the treatments they’ve received, according to a new study by researchers at Montefiore Health System and Albert Einstein College of Medicine. The findings, published online today in Nature Cancer, may lead to better care for cancer patients, who face a heightened risk of dying from COVID-19, and suggests that cancer patients should respond well to COVID-19 vaccines.
On Feb. 22, the University of California San Diego brought together a panel of industry experts and esteemed faculty to kick off the university’s “Evenings of Nonconventional Wisdom” online event series hosted in celebration of the university's 60th anniversary. To continue the timely dialogue around COVID-19 and vaccines, we reached back out to a few of the event panelists plus a leader from UC San Diego’s Return to Learn Program Dr. Robert “Chip” Schooley to answer questions submitted by the audience.
A new report shows parents are more vaccine hesitant and resistant than non-parents (in terms of willingness to vaccinate themselves) across all socioeconomic and demographic groups compared. This pattern is largely driven by younger mothers, who are far more vaccine resistant than younger women who are not mothers. Older parents and fathers show little difference from their non-parent peers.
The study will involve more than 2,000 residents, staff, and visitors of long-term care homes in Ontario over the course of a year. Blood and saliva will be examined.
The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains to the 30% of strains that were sensitive to the bnAb. This finding was seen both in Sub-Saharan Africa and the U.S. and South America. VRCO1 did not prevent the acquisition of HIV to strains that were resistant to the bNAb.
This is a landmark study in so far as being the first to raise the alarm that, despite early successes with Covid-19 vaccines, further research is warranted on a next generation of Covid-19 vaccines.
With topics ranging from the food we eat, the air we breathe, and the land we dwell on to the health of our body and mind, and the well-being of all things in the universe, this is a program that is for everyone and anyone. So, stay tuned and listen LIVE on Chula Radio Plus
Research reveals how mutated SARS-CoV-2 evades immune system defenses In lab-dish experiments, the mutant virus escaped antibodies from the plasma of COVID-19 survivors as well as pharmaceutical-grade antibodies Mutations arose in an immunocompromised patient with chronic SARS-CoV-2 infection Patient-derived virus harbored structural changes now seen cropping up independently in samples across the globe Findings underscore the need for better genomic surveillance to keep track of emerging variants Results highlight importance of therapies aimed at multiple targets on SARS-CoV-2 to minimize risk of resistance
Just 51% of Americans expressed a clear willingness to take the COVID-19 vaccine compared to 71% of residents in the United Kingdom, according to a new study conducted by Michigan State University's Quello Center during the first nine months of the pandemic. “The data suggests that due to the confusion that existed in American politics, with even our leaders at the highest levels casting doubt on the pandemic, the scientific message was muddled in the U.S., whereas in the U.K. there was a unifying voice,” said Johannes Bauer, director of MSU’s Quello Center and co-principal investigator on the research.
Front Line COVID-19 Critical Care Alliance to Convene Global Panel of Leading Experts to Discuss the Latest Research on Preventing and Treating COVID-19 with Ivermectin
People who talk with their doctors are more likely to get vaccinated during a pandemic, according to a study of evidence collected during the "swine flu," the last pandemic to hit the U.S. before COVID-19.
As the COVID-19 vaccine becomes more readily available to people across the country, many patients living with multiple sclerosis (MS), an often debilitating autoimmune disease of the central nervous system, are questioning whether patients on certain medications should get the shot.
ASA answers top-six questions patients may have about procedures
New guidelines from the U.S. Centers for Disease Control and Prevention open up the world just a bit for those fully vaccinated against COVID-19. But don’t toss away your collection of masks just yet.
States across the country should include blindness on the list of underlying conditions that makes a person eligible to receive the COVID-19 vaccine now.
Diez días después de recibida la segunda dosis de una vacuna de ARN mensajero, vacuna ARNm o vacuna contra la COVID-19, las personas sin síntomas de la enfermedad del coronavirus tienen mucho menos probabilidad de dar positivo para la infección y de propagarla sin saber que están enfermas que quienes aún no se han vacunado contra la COVID-19.
With the roll out of COVID-19 vaccines now underway, University of South Australia sleep experts are urging people to reprioritise their sleep, as getting regular and sufficient sleep is known to boost your immune system.
Fast-tracking clinical trials, vaccine delivery, and personal protective equipment through engineering: Live virtual event for March 11, 3PM ET
The American Cleaning Institute (ACI), the trade association for the cleaning product supply chain, joined the National Blue Ribbon Task Force to Stem COVID-19 Vaccine Hesitancy. This is a national effort spearheaded by The Creative Coalition in partnership with the Dean of the Yale University School of Public Health that brings together the most significant influencers and leaders in the U.S. in a national campaign aimed at reducing vaccine hesitancy across the most vulnerable communities.
An update from the ACAAI COVID-19 Vaccine Task Force on the risk of allergic reactions to COVID-19 vaccines - including the Johnson & Johnson vaccine
A Michigan Medicine team’s online guidelines have been viewed more than 30,000 times by providers in 150 countries since the beginning of the pandemic--and their deployment of an effective COVID-19 therapy has been a model for health systems and hospitals statewide.
Ten days after receiving a second dose of a messenger RNA, or mRNA, vaccine for COVID-19, patients without COVID-19 symptoms are far less likely to test positive and unknowingly spread COVID-19, compared to patients who have not been vaccinated for COVID-19. The Pfizer-BioNTech and Moderna messenger RNA vaccines for COVID-19 are authorized for emergency use in the U.S.
Nick Pullen, Ph.D., an associate professor of Biological Sciences at the University of Northern Colorado, shares his expertise on the COVID-19 vaccines and debunks some of the myths surrounding them.
A single shot of one of the currently authorized COVID-19 vaccines may be sufficient to provide immunity to individuals who have previously been infected by the virus, thus eliminating the need for a second dose and helping to stretch severely limited vaccine supplies, a study from Mount Sinai has found
Since its opening in January 2016, the Johns Hopkins Capacity Command Center has helped the Johns Hopkins Health System manage hospital operations — notably the flow of patients. So when the COVID-19 pandemic and the first people with the illness came to the hospital, the capacity command center was ready to manage the influx of patients.
A new SARS-CoV-2 vaccine candidate, developed by giving a key protein’s gene a ride into the body while encased in a measles vaccine, has been shown to produce a strong immune response and prevent SARS-CoV-2 infection and lung disease in multiple animal studies.
Last fall, many older adults were on the fence about getting a COVID-19 vaccine, according to a poll taken in October. But a new poll taken in late January shows a large uptick in positive attitudes, including among people over 50 who are Black, Hispanic or in fair or poor health.
As COVID-19 vaccines continue to be distributed, the world’s leading bone health research, clinical, and patient advocacy organizations ASBMR, Endocrine Society, AACE, ECTS, NOF, and IOF provide recommendations to assist clinicians in managing osteoporosis treatments for their patients who plan to get vaccinated. The full guidance document with supporting evidence is available at https://www.asbmr.org/about/statement-detail/joint-guidance-on-covid-19-vaccine-osteoporosis
The approval of COVID-19 vaccines has brought with it hope, excitement, as well as concerns. AARDA is committed to ensuring you have the information you need to make the right decisions for your health. A panel of medical experts will discuss frequently asked questions regarding COVID-19 vaccines, as well as address audience questions.
As the fight against COVID-19 continues, scientists have turned to an unlikely source for a potentially effective treatment: tiny antibodies naturally generated by llamas.
LifeBridge Health recently announced the launch of its “Care Happens Here” mobile unit, which will bring a wide range of healthcare testing and treatment services, including COVID-19 vaccinations, to vulnerable communities throughout central Maryland.
In a study conducted shortly before COVID-19 vaccines became available in the U.S., more than two-thirds of nursing home and assisted living staff in Indiana indicated willingness to receive a vaccine immediately or in the future.
Diphtheria - a relatively easily-preventable infection - is evolving to become resistant to a number of classes of antibiotics and in future could lead to vaccine escape, warn an international team of researchers from the UK and India.
A low-cost COVID-19 vaccine candidate that could be produced in the United States and worldwide using existing influenza virus manufacturing infrastructure has been developed by researchers at Icahn School of Medicine at Mount Sinai
A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center (VUMC) to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published in the journal Nature Medicine.
The body's immune response plays a crucial role in the course of a SARS-CoV-2 infection.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right